Can a simple blood test guide kidney transplant patients to fewer drugs?
NCT ID NCT04786067
First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study looked at 25 kidney transplant patients to see if a blood test measuring donor DNA could help them safely reduce their immunosuppressant medications to just one drug, belatacept. The goal was to see if this approach could prevent kidney rejection while simplifying treatment. Patients were monitored for rejection and other outcomes over 12 to 36 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT IMMUNOSUPPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belatacept
What this could lead to
If successful, this could allow some kidney transplant patients to take fewer immunosuppressant drugs, reducing side effects and simplifying their daily routine.
What could go wrong
This is a small, early-phase study with only 25 participants. The main risk is that reducing immunosuppression may lead to kidney rejection, which could damage the transplant.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.